{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:52:26Z","timestamp":1794473546763,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00863-1","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T07:30:42Z","timestamp":1745652642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus"],"prefix":"10.1038","volume":"5","author":[{"given":"Baolong","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-5197","authenticated-orcid":false,"given":"Simon J.","family":"Mountford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Jarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle R.","family":"Tilmanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-6876","authenticated-orcid":false,"given":"Belinda","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-6488","authenticated-orcid":false,"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5157","authenticated-orcid":false,"given":"Seiya","family":"Yamayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-8296","authenticated-orcid":false,"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-7625","authenticated-orcid":false,"given":"Philip E.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam A.","family":"Greenall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4252-086X","authenticated-orcid":false,"given":"Nadia","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"863_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-04788-w","volume":"607","author":"CJ Carlson","year":"2022","unstructured":"Carlson, C. J. et al. Climate change increases cross-species viral transmission risk. Nature 607, 555\u2013562 (2022).","journal-title":"Nature"},{"key":"863_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41586-021-04353-x","volume":"602","author":"VL Hale","year":"2022","unstructured":"Hale, V. L. et al. SARS-CoV-2 infection in free-ranging white-tailed deer. Nature 602, 481\u2013486 (2022).","journal-title":"Nature"},{"key":"863_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-020-03128-0","volume":"589","author":"AT Irving","year":"2021","unstructured":"Irving, A. T., Ahn, M., Goh, G., Anderson, D. E. & Wang, L. F. Lessons from the host defences of bats, a unique viral reservoir. Nature 589, 363\u2013370 (2021).","journal-title":"Nature"},{"key":"863_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","volume":"63","author":"RL Hoffman","year":"2020","unstructured":"Hoffman, R. L. et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J. Med Chem. 63, 12725\u201312747 (2020).","journal-title":"J. Med Chem."},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"863_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y Duan","year":"2023","unstructured":"Duan, Y. et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622, 376\u2013382 (2023).","journal-title":"Nature"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"863_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39704-x","volume":"14","author":"M Kiso","year":"2023","unstructured":"Kiso, M. et al. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat. Commun. 14, 3952 (2023).","journal-title":"Nat. Commun."},{"key":"863_CR10","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","volume":"9","author":"Y Hu","year":"2023","unstructured":"Hu, Y. et al. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. ACS Cent. Sci. 9, 1658\u20131669 (2023).","journal-title":"ACS Cent. Sci."},{"key":"863_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104559","volume":"91","author":"JD Ip","year":"2023","unstructured":"Ip, J. D. et al. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. eBioMedicine 91, 104559 (2023).","journal-title":"eBioMedicine"},{"key":"863_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","volume":"50","author":"SL Paiva","year":"2019","unstructured":"Paiva, S. L. & Crews, C. M. Targeted protein degradation: elements of PROTAC design. Curr. Opin. Chem. Biol. 50, 111\u2013119 (2019).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"863_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"863_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611\u2013617 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","volume":"25","author":"DP Bondeson","year":"2018","unstructured":"Bondeson, D. P. et al. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem. Biol. 25, 78\u201387.e75 (2018).","journal-title":"Cell Chem. Biol."},{"key":"863_CR16","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3390\/v14122711","volume":"14","author":"JA den Boon","year":"2022","unstructured":"den Boon, J. A. et al. Multifunctional Protein A Is the Only Viral Protein Required for Nodavirus RNA Replication Crown Formation. Viruses 14, 2711 (2022).","journal-title":"Viruses"},{"key":"863_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-015-0369-2","volume":"12","author":"P Deng","year":"2015","unstructured":"Deng, P., Wu, Z. & Wang, A. The multifunctional protein CI of potyviruses plays interlinked and distinct roles in viral genome replication and intercellular movement. Virol. J. 12, 141 (2015).","journal-title":"Virol. J."},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev-virology-101416-041654","volume":"4","author":"TB Faust","year":"2017","unstructured":"Faust, T. B., Binning, J. M., Gross, J. D. & Frankel, A. D. Making Sense of Multifunctional Proteins: Human Immunodeficiency Virus Type 1 Accessory and Regulatory Proteins and Connections to Transcription. Annu. Rev. Virol. 4, 241\u2013260 (2017).","journal-title":"Annu. Rev. Virol."},{"key":"863_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1021\/acs.jmedchem.8b01413","volume":"62","author":"V Zoppi","year":"2019","unstructured":"Zoppi, V. et al. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7. J. Med Chem. 62, 699\u2013726 (2019).","journal-title":"J. Med Chem."},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1074\/jbc.M116.768853","volume":"292","author":"N Ohoka","year":"2017","unstructured":"Ohoka, N. et al. In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs). J. Biol. Chem. 292, 4556\u20134570 (2017).","journal-title":"J. Biol. Chem."},{"key":"863_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm6638","volume":"8","author":"X Feng","year":"2022","unstructured":"Feng, X. et al. Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors. Sci. Adv. 8, eabm6638 (2022).","journal-title":"Sci. Adv."},{"key":"863_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5694\/mja2.50569","volume":"212","author":"L Caly","year":"2020","unstructured":"Caly, L. et al. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J. Aust. 212, 459\u2013462 (2020).","journal-title":"Med J. Aust."},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S1473-3099(22)00512-6","volume":"22","author":"GE Martin","year":"2022","unstructured":"Martin, G. E. et al. Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices. Lancet Infect. Dis. 22, 1417\u20131418 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"863_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18096-2","volume":"11","author":"W Vuong","year":"2020","unstructured":"Vuong, W. et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 11, 4282 (2020).","journal-title":"Nat. Commun."},{"key":"863_CR25","doi-asserted-by":"publisher","unstructured":"Sacco, M. D. et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. Sci Adv 6, https:\/\/doi.org\/10.1126\/sciadv.abe0751 (2020).","DOI":"10.1126\/sciadv.abe0751"},{"key":"863_CR26","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nchembio.2329","volume":"13","author":"MS Gadd","year":"2017","unstructured":"Gadd, M. S. et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 13, 514\u2013521 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"863_CR27","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","volume":"10","author":"M Zengerle","year":"2015","unstructured":"Zengerle, M., Chan, K. H. & Ciulli, A. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. ACS Chem. Biol. 10, 1770\u20131777 (2015).","journal-title":"ACS Chem. Biol."},{"key":"863_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jviromet.2011.02.013","volume":"173","author":"Y Fang","year":"2011","unstructured":"Fang, Y., Ye, P., Wang, X., Xu, X. & Reisen, W. Real-time monitoring of flavivirus induced cytopathogenesis using cell electric impedance technology. J. Virol. Methods 173, 251\u2013258 (2011).","journal-title":"J. Virol. Methods"},{"key":"863_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00491-22","volume":"10","author":"M Oeyen","year":"2022","unstructured":"Oeyen, M., Meyen, E., Doijen, J. & Schols, D. In-Depth Characterization of Zika Virus Inhibitors Using Cell-Based Electrical Impedance. Microbiol Spectr. 10, e0049122 (2022).","journal-title":"Microbiol Spectr."},{"key":"863_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","volume":"5","author":"MA Ramakrishnan","year":"2016","unstructured":"Ramakrishnan, M. A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 5, 85\u201386 (2016).","journal-title":"World J. Virol."},{"key":"863_CR31","doi-asserted-by":"publisher","first-page":"6776","DOI":"10.1074\/jbc.RA117.001091","volume":"293","author":"N Ohoka","year":"2018","unstructured":"Ohoka, N. et al. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor alpha degradation. J. Biol. Chem. 293, 6776\u20136790 (2018).","journal-title":"J. Biol. Chem."},{"key":"863_CR32","doi-asserted-by":"publisher","first-page":"27248","DOI":"10.1021\/jacs.3c12678","volume":"145","author":"X Sang","year":"2023","unstructured":"Sang, X. et al. A Chemical Strategy for the Degradation of the Main Protease of SARS-CoV-2 in Cells. J. Am. Chem. Soc. 145, 27248\u201327253 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"863_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1021\/acsmedchemlett.3c00498","volume":"15","author":"D Grifagni","year":"2024","unstructured":"Grifagni, D. et al. Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2. ACS Med. Chem. Lett. 15, 250\u2013257 (2024)","journal-title":"ACS Med. Chem. Lett."},{"key":"863_CR34","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","volume":"67","author":"YR Alugubelli","year":"2024","unstructured":"Alugubelli, Y. R. et al. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. J. Med Chem. 67, 6495\u20136507 (2024).","journal-title":"J. Med Chem."},{"key":"863_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116629","volume":"275","author":"S Cheng","year":"2024","unstructured":"Cheng, S. et al. Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses. Eur. J. Med. Chem. 275, 116629 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"863_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/22221751.2021.2023329","volume":"11","author":"H Zhao","year":"2022","unstructured":"Zhao, H. et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microbes Infect. 11, 277\u2013283 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"863_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add7197","volume":"8","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci. Adv. 8, eadd7197 (2022).","journal-title":"Sci. Adv."},{"key":"863_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s44259-023-00009-0","volume":"1","author":"SA Moghadasi","year":"2023","unstructured":"Moghadasi, S. A., Biswas, R. G., Harki, D. A. & Harris, R. S. Rapid resistance profiling of SARS-CoV-2 protease inhibitors. npj Antimicrobials Resistance 1, 9 (2023).","journal-title":"npj Antimicrobials Resistance"},{"key":"863_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/cid\/ciad494","volume":"78","author":"NS Zuckerman","year":"2023","unstructured":"Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir Resistance\u2014de Novo E166V\/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir\/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure\u2014a Case Report. Clin. Infect. Dis. 78, 352\u2013355 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"863_CR40","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","volume":"57","author":"AD Buhimschi","year":"2018","unstructured":"Buhimschi, A. D. et al. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton\u2019s Tyrosine Kinase Using PROTAC-Mediated Degradation. Biochemistry 57, 3564\u20133575 (2018).","journal-title":"Biochemistry"},{"key":"863_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11429-w","volume":"10","author":"M de Wispelaere","year":"2019","unstructured":"de Wispelaere, M. et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 10, 3468 (2019).","journal-title":"Nat. Commun."},{"key":"863_CR42","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.chembiol.2024.02.004","volume":"31","author":"LA Emert-Sedlak","year":"2024","unstructured":"Emert-Sedlak, L. A. et al. PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication. Cell Chem. Biol. 31, 658\u2013668 e614 (2024).","journal-title":"Cell Chem. Biol."},{"key":"863_CR43","doi-asserted-by":"publisher","first-page":"16930","DOI":"10.1021\/jacs.2c05499","volume":"144","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2. J. Am. Chem. Soc. 144, 16930\u201316952 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"863_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.37349\/etat.2020.00018","volume":"1","author":"RI Troup","year":"2020","unstructured":"Troup, R. I., Fallan, C. & Baud, M. G. J. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther. 1, 273\u2013312 (2020).","journal-title":"Explor Target Antitumor Ther."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00863-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00863-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00863-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T09:02:35Z","timestamp":1745658155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00863-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00863-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3932156\/v1","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}